RIGEL PHARMACEUTICALS, INC. Stock-Based Compensation
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Stock-Based Compensation of $10.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $6.84M, a 108.91% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.46M, a 3.97% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.75M, a 31.67% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.36M, a 27.19% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $12.71M, a 2.57% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $12.39M, a 40.73% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $8.81M, a 28.90% decline from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $12.38M, a 30.56% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $10.30M 10-Q · filed 2026-08-04 | $13.05M derived: sum of 3 quarters · filed 2026-08-04 | $16.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.46M 10-Q · filed 2026-05-05 | $6.20M derived: sum of 2 quarters · filed 2026-05-05 | $9.57M derived: sum of 3 quarters · filed 2026-05-05 | $12.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.11M derived: sum of 2 quarters · filed 2026-03-03 | $9.39M derived: sum of 3 quarters · filed 2026-08-04 | $12.71M 10-K · filed 2026-03-03 |
| 2025-09-30 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.64M derived: sum of 2 quarters · filed 2026-08-04 | $9.96M 10-Q · filed 2025-11-04 | $12.05M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.60M 10-Q · filed 2026-08-04 | $8.69M derived: sum of 3 quarters · filed 2026-08-04 | $11.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.32M 10-Q · filed 2026-05-05 | $5.41M derived: sum of 2 quarters · filed 2026-05-05 | $8.05M derived: sum of 3 quarters · filed 2026-05-05 | $10.58M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.73M derived: sum of 2 quarters · filed 2026-03-03 | $7.26M derived: sum of 3 quarters · filed 2026-03-03 | $12.39M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.17M derived: sum of 2 quarters · filed 2025-11-04 | $10.31M 10-Q · filed 2025-11-04 | $12.24M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.66M 10-Q · filed 2025-08-05 | $9.60M derived: sum of 3 quarters · filed 2026-03-03 | $11.54M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $5.13M 10-Q · filed 2025-05-06 | $7.07M derived: sum of 2 quarters · filed 2026-03-03 | $9.01M derived: sum of 3 quarters · filed 2026-03-03 | $11.18M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.88M derived: sum of 2 quarters · filed 2026-03-03 | $6.05M derived: sum of 3 quarters · filed 2026-03-03 | $8.81M 10-K · filed 2026-03-03 |
| 2023-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.12M derived: sum of 2 quarters · filed 2024-11-07 | $6.87M 10-Q · filed 2024-11-07 | $10.95M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.93M 10-Q · filed 2024-08-06 | $9.01M derived: sum of 3 quarters · filed 2025-03-04 | $11.72M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $2.76M 10-Q · filed 2024-05-07 | $6.84M derived: sum of 2 quarters · filed 2025-03-04 | $9.54M derived: sum of 3 quarters · filed 2025-03-04 | $11.94M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $6.79M derived: sum of 2 quarters · filed 2025-03-04 | $9.18M derived: sum of 3 quarters · filed 2025-03-04 | $12.38M 10-K · filed 2025-03-04 |
| 2022-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.10M derived: sum of 2 quarters · filed 2023-11-07 | $8.30M 10-Q · filed 2023-11-07 | $10.64M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $5.60M 10-Q · filed 2023-08-01 | $7.94M derived: sum of 3 quarters · filed 2024-03-05 | $10.14M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $3.21M 10-Q · filed 2023-05-02 | $5.55M derived: sum of 2 quarters · filed 2024-03-05 | $7.75M derived: sum of 3 quarters · filed 2024-03-05 | $10.05M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $4.54M derived: sum of 2 quarters · filed 2024-03-05 | $6.85M derived: sum of 3 quarters · filed 2024-03-05 | $9.49M 10-K · filed 2024-03-05 |
| 2021-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.51M derived: sum of 2 quarters · filed 2022-11-03 | $7.15M 10-Q · filed 2022-11-03 | $8.78M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $4.95M 10-Q · filed 2022-08-02 | $6.58M derived: sum of 3 quarters · filed 2023-03-07 | $8.46M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $2.64M 10-Q · filed 2022-05-03 | $4.27M derived: sum of 2 quarters · filed 2023-03-07 | $6.16M derived: sum of 3 quarters · filed 2023-03-07 | $7.91M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $3.52M derived: sum of 2 quarters · filed 2023-03-07 | $5.27M derived: sum of 3 quarters · filed 2023-03-07 | $7.30M 10-K · filed 2023-03-07 |
| 2020-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.64M derived: sum of 2 quarters · filed 2021-11-02 | $5.67M 10-Q · filed 2021-11-02 | $7.08M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $3.78M 10-Q · filed 2021-08-03 | $5.19M derived: sum of 3 quarters · filed 2022-03-01 | $7.29M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.02M 10-Q · filed 2021-05-05 | $3.44M derived: sum of 2 quarters · filed 2022-03-01 | $5.53M derived: sum of 3 quarters · filed 2022-03-01 | $8.19M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.51M derived: sum of 2 quarters · filed 2022-03-01 | $6.16M derived: sum of 3 quarters · filed 2022-03-01 | $9.12M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.75M derived: sum of 2 quarters · filed 2020-11-05 | $7.70M 10-Q · filed 2020-11-05 | $9.76M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $5.61M 10-Q · filed 2020-08-04 | $7.66M derived: sum of 3 quarters · filed 2021-03-02 | $10.66M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | $2.95M 10-Q · filed 2020-05-05 | $5.01M derived: sum of 2 quarters · filed 2021-03-02 | $8.01M derived: sum of 3 quarters · filed 2021-03-02 | $9.12M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $5.05M derived: sum of 2 quarters · filed 2021-03-02 | $6.16M derived: sum of 3 quarters · filed 2021-03-02 | $7.70M 10-K · filed 2021-03-02 |
| 2018-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $4.11M derived: sum of 2 quarters · filed 2019-11-05 | $5.65M 10-Q · filed 2019-11-05 | $8.71M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.65M 10-Q · filed 2019-08-06 | $5.71M derived: sum of 3 quarters · filed 2020-02-27 | $6.58M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $1.54M 10-Q · filed 2019-05-07 | $4.60M derived: sum of 2 quarters · filed 2020-02-27 | $5.47M derived: sum of 3 quarters · filed 2020-02-27 | $6.57M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $3.93M derived: sum of 2 quarters · filed 2020-02-27 | $5.03M derived: sum of 3 quarters · filed 2020-02-27 | $5.99M 10-K · filed 2020-02-27 |
| 2017-09-30 | $873.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.97M derived: sum of 2 quarters · filed 2018-11-06 | $2.93M 10-Q · filed 2018-11-06 | $5.59M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $2.06M 10-Q · filed 2018-08-08 | $4.72M derived: sum of 3 quarters · filed 2019-02-28 | $5.94M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $955.00K 10-Q · filed 2018-05-01 | $3.62M derived: sum of 2 quarters · filed 2019-02-28 | $4.84M derived: sum of 3 quarters · filed 2019-02-28 | $6.85M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $3.88M derived: sum of 2 quarters · filed 2019-02-28 | $5.89M derived: sum of 3 quarters · filed 2019-02-28 | $7.33M 10-K · filed 2019-02-28 |
| 2016-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.23M derived: sum of 2 quarters · filed 2017-11-07 | $4.67M 10-Q · filed 2017-11-07 | $6.29M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $3.45M 10-Q · filed 2017-08-01 | $5.08M derived: sum of 3 quarters · filed 2018-03-06 | $6.89M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | $1.44M 10-Q · filed 2017-05-02 | $3.06M derived: sum of 2 quarters · filed 2018-03-06 | $4.88M derived: sum of 3 quarters · filed 2018-03-06 | $6.79M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $3.44M derived: sum of 2 quarters · filed 2018-03-06 | $5.35M derived: sum of 3 quarters · filed 2018-03-06 | $7.40M 10-K · filed 2018-03-06 |
| 2015-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $3.72M derived: sum of 2 quarters · filed 2016-11-01 | $5.78M 10-Q · filed 2016-11-01 | $8.99M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $3.96M 10-Q · filed 2016-08-02 | $7.17M derived: sum of 3 quarters · filed 2017-03-07 | $9.25M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-03-31 | $2.05M 10-Q · filed 2016-05-03 | $5.26M derived: sum of 2 quarters · filed 2017-03-07 | $7.34M derived: sum of 3 quarters · filed 2017-03-07 | $9.48M derived: sum of 4 quarters · filed 2017-03-07 |
| 2014-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $5.29M derived: sum of 2 quarters · filed 2017-03-07 | $7.42M derived: sum of 3 quarters · filed 2017-03-07 | $9.79M 10-K · filed 2017-03-07 |
| 2014-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $4.21M derived: sum of 2 quarters · filed 2015-11-03 | $6.58M 10-Q · filed 2015-11-03 | $8.14M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $4.50M 10-Q · filed 2015-08-04 | $6.06M derived: sum of 3 quarters · filed 2016-03-08 | $8.12M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-03-31 | $2.36M 10-Q · filed 2015-05-07 | $3.93M derived: sum of 2 quarters · filed 2016-03-08 | $5.99M derived: sum of 3 quarters · filed 2016-03-08 | $7.74M derived: sum of 4 quarters · filed 2016-03-08 |
| 2013-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $3.63M derived: sum of 2 quarters · filed 2016-03-08 | $5.37M derived: sum of 3 quarters · filed 2016-03-08 | $7.17M 10-K · filed 2016-03-08 |
| 2013-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $3.81M derived: sum of 2 quarters · filed 2014-11-04 | $5.60M 10-Q · filed 2014-11-04 | $8.87M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $3.54M 10-Q · filed 2014-08-05 | $6.80M derived: sum of 3 quarters · filed 2015-03-03 | $10.05M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-03-31 | $1.79M 10-Q · filed 2014-05-07 | $5.06M derived: sum of 2 quarters · filed 2015-03-03 | $8.30M derived: sum of 3 quarters · filed 2015-03-03 | $11.31M derived: sum of 4 quarters · filed 2015-03-03 |
| 2012-12-31 | $3.26M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $6.51M derived: sum of 2 quarters · filed 2015-03-03 | $9.52M derived: sum of 3 quarters · filed 2015-03-03 | $12.62M 10-K · filed 2015-03-03 |
| 2012-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $6.26M derived: sum of 2 quarters · filed 2013-11-05 | $9.35M 10-Q · filed 2013-11-05 | $12.39M derived: sum of 4 quarters · filed 2014-03-04 |
| 2012-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $6.11M 10-Q · filed 2013-08-06 | $9.15M derived: sum of 3 quarters · filed 2014-03-04 | $12.24M derived: sum of 4 quarters · filed 2014-03-04 |
| 2012-03-31 | $3.10M 10-Q · filed 2013-05-07 | $6.14M derived: sum of 2 quarters · filed 2014-03-04 | $9.23M derived: sum of 3 quarters · filed 2014-03-04 | $12.43M derived: sum of 4 quarters · filed 2014-03-04 |
| 2011-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-04 | $6.13M derived: sum of 2 quarters · filed 2014-03-04 | $9.33M derived: sum of 3 quarters · filed 2014-03-04 | $13.17M 10-K · filed 2014-03-04 |
| 2011-09-30 | $3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $6.29M derived: sum of 2 quarters · filed 2012-11-06 | $10.13M 10-Q · filed 2012-11-06 | $13.93M derived: sum of 4 quarters · filed 2013-03-05 |
| 2011-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $7.04M 10-Q · filed 2012-08-07 | $10.84M derived: sum of 3 quarters · filed 2013-03-05 | $14.61M derived: sum of 4 quarters · filed 2013-03-05 |
| 2011-03-31 | $3.84M 10-Q · filed 2012-05-01 | $7.64M derived: sum of 2 quarters · filed 2013-03-05 | $11.40M derived: sum of 3 quarters · filed 2013-03-05 | |
| 2010-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-05 | $7.57M derived: sum of 2 quarters · filed 2013-03-05 | $16.44M 10-K · filed 2013-03-05 | |
| 2010-09-30 | $3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $12.63M 10-Q · filed 2011-11-01 | ||
| 2010-06-30 | $8.87M 10-Q · filed 2011-08-02 | |||
| 2009-12-31 | $13.44M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |